Welcome to our dedicated page for EUDA Health Holdings news (Ticker: EUDA), a resource for investors and traders seeking the latest updates and insights on EUDA Health Holdings stock.
EUDA Health Holdings Limited reports developments across non-invasive and preventive healthcare in Asia, with a focus on Singapore, Malaysia and China. Company updates include longevity and personalized healthcare services, regenerative medicine access, stem cell extraction and cryogenic storage, and commercial arrangements for selected cellular immunotherapies, including TCR-T-related therapies supplied through Shenzhen Inno Immune.
EUDA announcements also cover public-company capital actions and Nasdaq listing matters. Recent corporate developments include ordinary-share adjustments, warrant amendments and cancellations, registered share offerings, and governance actions tied to its capital structure as a Nasdaq-listed foreign private issuer.
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Chemokine Pte. Ltd. The supplement, branded as Euda Helixé, will initially launch in Singapore, Malaysia, and China.
The advanced formulation features premium ingredients including deer placenta, L-Glutathione, and marine collagen, utilizing epigenetic technology to modulate gene expression. The supplement aims to enhance metabolism, boost vitality, and support longevity through its specialized capsule delivery system.
CEO Alfred Lim projects potential sales of 500,000 bottles within the next 12 months, representing a significant opportunity for revenue diversification.
EUDA Health Holdings (NASDAQ: EUDA) has announced an update to its previously disclosed strategic partnership with Guangdong Cell Biotech. Instead of forming a joint venture, the companies have opted for a commercial distribution arrangement through EUDA's subsidiary CK Health Plus Sdn Bhd.
On April 22, 2025, CK Health signed a collaboration agreement with Keylock, an authorized distributor of Guangdong Cell Biotech, enabling EUDA to market and sell stem cell therapies to customers in Singapore and Malaysia. The therapies will be provided by Guangdong Cell Biotech in China.
This strategic move aligns with EUDA's mission to expand access to holistic healthcare solutions in Southeast Asia while diversifying its business and revenue streams. The partnership leverages Guangdong Cell Biotech's expertise in stem cell therapies and regenerative medicine for various disorders.
EUDA Health Holdings (NASDAQ: EUDA) has initiated preliminary discussions with Guangdong Cell Biotech to establish a joint venture, combining EUDA's digital healthcare ecosystem with Guangdong's stem cell therapy expertise. The potential partnership aims to deliver regenerative therapies across Southeast Asia through EUDA's platform.
Guangdong Cell Biotech currently operates 37 stem cell and DNA medical treatment facilities in China, with presence in Indonesia and Cambodia. The collaboration would focus on developing a comprehensive framework for 'digital health + digital healthcare + digital stem cell therapy' while expanding market presence and generating operational synergies.
The partnership remains in early discussion stages, with no legally binding agreement or letter of intent signed yet.
EUDA Health Holdings has successfully completed the acquisition of CK Health Plus Sdn Bhd, expanding its presence in Malaysia and venturing into direct selling of holistic wellness products in Southeast Asia. The acquisition provides EUDA with access to CK Health's distribution network, customer base, and industry expertise, enhancing its regional market position and product portfolio.
EUDA Health Holdings (EUDA) announced the acquisition of CK Health Plus Sdn Bhd, a direct seller of holistic wellness products in Malaysia, for 10 million shares valued at US$15 million. The deal is set to close on 8th May 2024. CK Health's products focus on non-invasive therapies and exclusive distribution rights for bioenergy cabins and collagen products. EUDA plans to integrate these products into its offerings to target chronic conditions and tap into Southeast Asia's growing healthcare market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.